Company Overview of Ora, Inc.
Ora, Inc. provides clinical research and drug development services. The company offers pre-clinical research, animal toxicology studies, and compounds identification and procurement services. Additionally, it provides clinical consulting, data management, statistical analysis, and medical writing services. The company also offers strategic planning, speaker training, media planning and placement, and public relations services. Ora, Inc., formerly known as Ophthalmic Research Associates, Inc., is based in Andover, Massachusetts.
300 Brickstone Square
Andover, MA 01810
Founded in 1985
Key Executives for Ora, Inc.
Chief Executive Officer and President
Senior Vice President and Chief Operating Officer
Vice President of Business Development
Director of Allergy Research
Vice President of Dry Eye Research
Compensation as of Fiscal Year 2015.
Ora, Inc. Key Developments
Ora-CAC Model Delivers Successful Phase 3 Data for Ocular Therapeutix's DEXTENZA (OTX- DP) for Treatment of Allergic Conjunctivitis
Nov 12 15
Ora Inc. announced that its Conjunctival Allergen Challenge (Ora-CAC®) model recently confirmed Phase 2 clinical results of Sustained Release Dexamethasone (OTX-DP), a drug-eluting intracanalicular depot, under development by Ocular Therapeutix as DEXTENZA, for the treatment of chronic allergic conjunctivitis. DEXTENZA achieved 1-unit difference from vehicle in ocular itching, which has previously been the FDA standard for approval of therapies in this disease.
BioLight Life Sciences Investments Expands Relationship with Ora, Inc. to Advance the Clinical, Regulatory and Commercial Development of BioLight's TeaRx
Jun 15 15
BioLight Life Sciences Investments announced that it has expanded its relationship with Ora, Inc., via the signing of a Collaboration Agreement pursuant to which the companies will work together to advance the clinical, regulatory and commercial development of BioLight's TeaRx multi-parameter diagnostic test for dry eye syndrome. While financial terms were not disclosed, BioLight advised that, the company and Ora will jointly fund the clinical study and other activities required to obtain USD 510,000 regulatory approval for the TeaRx multi-parameter diagnostic test for DES. BioLight also granted Ora the right to incorporate the TeaRx test in other clinical trials sponsored by third parties and performed by Ora.
Portola Pharmaceuticals Announces Collaboration with Ora, Inc. for Syk-Selective Inhibitor in Ophthalmic Diseases
May 5 15
Portola Pharmaceuticals announced a collaboration with Ora, Inc. for the development of Portola's highly selective Syk inhibitor, PRT2761, in ophthalmic diseases. The inhibition of Syk may more completely prevent activation of mast cells in ocular allergy and, therefore, a Syk inhibitor could represent a promising therapeutic option. This collaboration for PRT2761 is part of a strategy that allows to advance early-stage compounds outside of key focus on thrombosis and hematologic cancer with innovative companies that have the expertise and resources to develop these agents to proof-of-concept. Portola's highly specific Syk inhibitor PRT2761 has the potential to deliver rapid onset of action and comprehensive treatment of both signs and symptoms of ocular allergy, including redness, inflammation, swelling and itching.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|